Market revenue in 2023 | USD 15.5 million |
Market revenue in 2030 | USD 23.7 million |
Growth rate | 6.2% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35.48% in 2023. Horizon Databook has segmented the Canada cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
The cell and gene therapy bioanalytical testing services market in Canada is growing as a result of increasing investments, collaborations, and other strategic initiatives undertaken by global biopharmaceutical companies that conduct research in healthcare illness domains.
It is projected that Canada's well-established biotechnology industry will drive the market for cell and gene therapy bioanalytical testing services in this country. For instance, in September 2023, to enhance bioanalytical abilities and expedite the implementation of complex clinical trials, Cerba HealthCare successfully acquired CIRION BioPharma Research, a Canadian contract research laboratory.
This strategic move demonstrates the organization's objective of providing its clinical research clients with enhanced flexibility and top-notch scientific insights to support their drug development projects. The acquisition is expected to enhance proficiency in immunogenicity testing and Pharmacokinetic/Pharmacodynamics (PK/PD) testing, hence offering essential support to the pharmaceutical sector.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into Canada cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account